The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
In Vitro Pharmacological Characterization of Vilanterol, a Novel Long-Acting β2-Adrenoceptor Agonist with 24-Hour Duration of Action
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global strategy for asthma management and prevention: GINA executive summary
Bateman, E. D., Hurd, S. S., Barnes, P. J., Bousquet, J., Drazen, J. M., FitzGerald, M., Gibson, P., Ohta, K., O'Byrne, P., Pedersen, S. E., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00138707 · Cited by 3,203
Research works printed but not linked: 38
- Anderson, 1993, Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator, Life Sci, 52, 2145, 10.1016/0024-3205(93)90729-M · DOI · Paper page
- Anderson, 1994, Why are long-acting beta-adrenoceptor agonists long-acting?, Eur Respir J, 7, 569, 10.1183/09031936.94.07030569 · doi:10.1183/09031936.94.07030569
- Baker, 2005, The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors, Br J Pharmacol, 144, 317, 10.1038/sj.bjp.0706048 · DOI · Paper page
- Baker, 2010, The selectivity of β-adrenoceptor agonists at human β1-, β2- and β3-adrenoceptors, Br J Pharmacol, 160, 1048, 10.1111/j.1476-5381.2010.00754.x · DOI · Paper page
- Ball, 1991, Salmeterol, a novel, long-acting β2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo, Br J Pharmacol, 104, 665, 10.1111/j.1476-5381.1991.tb12486.x · DOI · Paper page
- Battram, 2006, In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled β2 adrenoceptor agonist with a 24-h duration of action, J Pharmacol Exp Ther, 317, 762, 10.1124/jpet.105.098251 · DOI · Paper page
- Broadley, 2006, β-adrenoceptor responses of the airways: for better or worse?, Eur J Pharmacol, 533, 15, 10.1016/j.ejphar.2005.12.060 · DOI
- Busse, 2001, Asthma, N Engl J Med, 344, 350, 10.1056/NEJM200102013440507 · DOI · Paper page
- Casarosa, 2011, Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol, J Pharmacol Exp Ther, 337, 600, 10.1124/jpet.111.179259 · doi:10.1124/jpet.111.179259
- Cazzola, 2011, β2-adrenoceptor agonists: current and future direction, Br J Pharmacol, 163, 4, 10.1111/j.1476-5381.2011.01216.x · DOI · Paper page
- Cazzola, 2010, The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD, Pulm Pharmacol Ther, 23, 257, 10.1016/j.pupt.2010.03.003 · DOI · Paper page
- Celli, 2004, Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper, Eur Respir J, 23, 932, 10.1183/09031936.04.00014304 · DOI · Paper page
- Cheng, 1973, Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction, Biochem Pharmacol, 22, 3099, 10.1016/0006-2952(73)90196-2 · DOI · Paper page
- Coleman, 1996, Exosites: their current status, and their relevance to the duration of action of long-acting β2-adrenoceptor agonists, Trends Pharmacol Sci, 17, 324, 10.1016/0165-6147(96)10040-7 · DOI
- Contreras, 1986, Thermodynamic properties of agonist interactions with the beta adrenergic receptor-coupled adenylate cyclase system. I. High- and low-affinity states of agonist binding to membrane-bound beta adrenergic receptors, J Pharmacol Exp Ther, 237, 154, 10.1016/S0022-3565(25)24907-2 · DOI
- Cullum, 1969, Salbutamol: a new, selective β-adrenoceptive receptor stimulant, Br J Pharmacol, 35, 141, 10.1111/j.1476-5381.1969.tb07975.x · DOI · Paper page
- Hanania, 2012, The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial, Chest, 142, 119, 10.1378/chest.11-2231 · doi:10.1378/chest.11-2231
- Hill, 1909, The mode of action of nicotine and curari, determined by the form of the contraction curve and the method of temperature coefficients, J Physiol, 39, 361, 10.1113/jphysiol.1909.sp001344 · DOI · Paper page
- Hirst, 2010, Use of long-acting β-agonists and inhaled steroids in asthma: meta-analysis of observational studies, J Asthma, 47, 439, 10.3109/02770901003605340 · doi:10.3109/02770901003605340
- Holm, 1979, A simple sequentially rejective multiple test procedure, Scand J Stat, 6, 65
- Johnson, 2002, Heterotrimeric G protein signaling: role in asthma and allergic inflammation, J Allergy Clin Immunol, 109, 592, 10.1067/mai.2002.122636 · DOI
- Johnson, 1993, The pharmacology of salmeterol, Life Sci, 52, 2131, 10.1016/0024-3205(93)90728-L · DOI
- Kardos, 2006, Tackling COPD: a multicomponent disease driven by inflammation, Med Gen Med, 8, 54
- Lotvall, 2012, 24h duration of the novel LABA vilanterol trifenatate in asthma patients treated with ICSs, Eur Respir J, 40, 570, 10.1183/09031936.00121411 · DOI
- Malerba, 2012, Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects, Drug Discov Today, 17, 496, 10.1016/j.drudis.2011.11.002 · doi:10.1016/j.drudis.2011.11.002
- Nelson, 2006, The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol, Chest, 129, 15, 10.1378/chest.129.1.15 · DOI · Paper page
- Patel, 2011, The reassertion profiles of long acting β2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant β2-adrenoceptor, Pulm Pharmacol Ther, 24, 247, 10.1016/j.pupt.2010.11.004 · doi:10.1016/j.pupt.2010.11.004
- Procopiou PA, Barrett VJ, Bevan NJ, Biggadike K, Box PC, Butchers PR, Coe DM, Conroy R, Emmons A, Ford AJ et al. (2010) Synthesis and structure-activity relationships of long-acting β2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem 53:4522–4530. · doi:10.1021/jm100326d
- Rosethorne, 2010, Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled β2-adrenoceptor agonists, Naunyn Schmiedebergs Arch Pharmacol, 382, 255, 10.1007/s00210-010-0533-6 · doi:10.1007/s00210-010-0533-6
- Samama, 1993, A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model, J Biol Chem, 268, 4625, 10.1016/S0021-9258(18)53442-6 · DOI · Paper page
- Smith, 1985, Measurement of protein using bicinchoninic acid, Anal Biochem, 150, 76, 10.1016/0003-2697(85)90442-7 · DOI · Paper page
- Sturton, 2008, Pharmacological characterization of indacaterol, a novel once daily inhaled β2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices, J Pharmacol Exp Ther, 324, 270, 10.1124/jpet.107.129296 · DOI
- Summerhill, 2008, A cell-based assay to assess the persistence of action of agonists acting at recombinant human β2 adrenoceptors, J Pharmacol Toxicol Methods, 58, 189, 10.1016/j.vascn.2008.06.003 · DOI
- Szczuka, 2009, Molecular mechanisms for the persistent bronchodilatory effect of the β2-adrenoceptor agonist salmeterol, Br J Pharmacol, 158, 183, 10.1111/j.1476-5381.2009.00296.x · doi:10.1111/j.1476-5381.2009.00296.x
- Tashkin, 2005, Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease?, Curr Opin Pulm Med, 11, 121, 10.1097/00063198-200503000-00004 · DOI
- Toews, 1983, High-affinity binding of agonists to β-adrenergic receptors on intact cells, Proc Natl Acad Sci USA, 80, 3553, 10.1073/pnas.80.12.3553 · DOI
- Waldeck, 2002, β-adrenoceptor agonists and asthma—100 years of development, Eur J Pharmacol, 445, 1, 10.1016/S0014-2999(02)01728-4 · DOI · Paper page
- Wallace, 1983, Temperature dependence of the binding of [3H]mepyramine and related compounds to the histamine H1 receptor, Mol Pharmacol, 23, 60, 10.1016/S0026-895X(25)14230-2 · doi:10.1016/s0026-895x(25)14230-2
Cited by
Dransfield, M. T., Bourbeau, J., Jones, P. W., Hanania, N. A., Mahler, D. A., Vestbo, J., Wachtel, A., Martinez, F. J., Barnhart, F., Sanford, L., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70040-7 · Cited by 345
β 2 -Agonist Therapy in Lung Disease
Cazzola, M., Page, C. P., Rogliani, P., & Matera, M. G. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201209-1739pp · Cited by 262
Metadata
- Authors
- Slack, R. J., Barrett, V. J., Morrison, V. S., Sturton, R. G., Emmons, A. J., Ford, A. J., & Knowles, R. G.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 344
- Issue
- 1
- Pages
- 218-230
- ISSN
- 0022-3565
- Cited by
- 99
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.